Form D · Pharmaceuticals

Sunshine Biopharma, Inc

Pointe Claire, A8 · CIK 0001402328

Offering snapshot reported May 17, 2023 · SEC filing

Reported sold
$5M
Offering amount: $5M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 12, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 17, 2023Initial$4,996,497No comparison1SEC filing
Apr 29, 2022Initial$19,497,618No comparison9SEC filing
Mar 18, 2022Initial$7,998,699No comparison9SEC filing
Aug 24, 2012Initial$459,313No comparison7SEC filing
May 25, 2007PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$600K
Finders' fees
$0
Form D file number
021-481966

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Aegis Capital Corp.15007

Source: Form D, filed May 17, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Michele Di Turi Director, Executive
Andrew Keller Director
Rabi Kiderach Director
Rabi Kiderchah Director
Abderrazzak Merzouki Director, Executive
David Natan Director
Camille Sebaaly Executive
Steve N. Slilaty Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
6500 Trans Canada Highway 4 Th Floor
Pointe Claire, A8, H9R 0A5